Literature DB >> 12574232

The human myometrium as a target for melatonin.

N Schlabritz-Loutsevitch1, N Hellner, R Middendorf, D Müller, J Olcese.   

Abstract

The circadian timing of spontaneous human deliveries results in births occurring statistically more often during the nocturnal phase of the 24-h cycle. The neuroendocrine mechanisms underlying this physiological phenomenon are not understood. In an effort to test the hypothesis that melatonin may serve as an endocrine signal for coordinating myometrial events in the human, we determined the mRNA expression of both MT1 and MT2 melatonin receptor isoforms in pregnant as well as nonpregnant myometrial biopsies by means of RT-PCR and in situ hybridization histochemistry. Additionally, we could demonstrate specific, high affinity iodomelatonin binding to myometrial tissues of both pregnant and nonpregnant women. Primary cultures of myocytes responded differentially from melatonin in terms of cAMP signaling depending on the reproductive state. These results imply that melatonin may have the potential to modulate myometrial function in the human, a finding that could open up new possibilities for the development of novel therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574232     DOI: 10.1210/jc.2002-020449

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 2.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

3.  Relationship between endogenous melatonin concentrations and uterine contractions in late third trimester of human pregnancy.

Authors:  Shadab A Rahman; Carolina Bibbo; James Olcese; Charles A Czeisler; Julian N Robinson; Elizabeth B Klerman
Journal:  J Pineal Res       Date:  2019-03-10       Impact factor: 13.007

4.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

5.  Melatonin activity and receptor expression in endometrial tissue and endometriosis.

Authors:  A A Mosher; M W Tsoulis; J Lim; C Tan; S K Agarwal; N A Leyland; W G Foster
Journal:  Hum Reprod       Date:  2019-07-08       Impact factor: 6.918

Review 6.  Extrapineal melatonin: sources, regulation, and potential functions.

Authors:  Darío Acuña-Castroviejo; Germaine Escames; Carmen Venegas; María E Díaz-Casado; Elena Lima-Cabello; Luis C López; Sergio Rosales-Corral; Dun-Xian Tan; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

7.  Dual effects of melatonin on uterine myoelectrical activity of non-pregnant rats.

Authors:  Yavuz Simşek; Hakan Parlakpınar; Uğur Turhan; Mehmet Emin Tağluk; Burhan Ateş
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-06-01

8.  Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells.

Authors:  James T Sharkey; Roopashri Puttaramu; R Ann Word; James Olcese
Journal:  J Clin Endocrinol Metab       Date:  2008-11-11       Impact factor: 5.958

Review 9.  Peripheral reproductive organ health and melatonin: ready for prime time.

Authors:  Russel J Reiter; Sergio A Rosales-Corral; Lucien C Manchester; Dun-Xian Tan
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

10.  Potency of melatonin in living beings.

Authors:  Donchan Choi
Journal:  Dev Reprod       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.